Anti-oxidized cholesterol antibodies

Anti-cholesterol antibodies were first reported 80 years ago.

Numerous studies have since shown that human subjects with peripheral atherosclerosis and cerebrovascular disease have low levels of these circulating antibodies to cholesterol.

We believe that our immune system produces anti-cholesterol antibodies in response to elevated levels of oxidized cholesterol-rich particles, such as LDL and VLDL. Unfortunately, in many cases, the levels of these antibodies to cholesterol are not sufficient to protect us against atherosclerosis.

When ingested, this antibody binds to oxidized cholesterol-rich micelles in the small intestine and thereby blocks the absorption of cholesterol into the bloodstream.

Origo has multiple patent applications under review by the USPTO for the use of orally administered anti-oxidized cholesterol for the atherosclerosis.

Selected References